Aptevo Therapeutics Inc.
APVO
$4.83
-$0.02-0.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.61% | -11.60% | 3.72% | 12.27% | -38.59% |
| Total Depreciation and Amortization | -31.82% | -42.07% | -39.22% | -37.98% | -37.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.37% | -25.15% | -33.85% | -18.38% | -1.54% |
| Change in Net Operating Assets | 51.75% | 31.64% | -31.42% | -222.99% | -174.75% |
| Cash from Operations | -7.60% | -12.18% | -1.45% | -3.32% | -102.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 154.49% | 226.58% | 124.62% | 92.14% | 59.65% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 50.00% | 90.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 15,833.33% | 15,833.33% | 15,833.33% | -- |
| Cash from Financing | 146.85% | 230.70% | 128.89% | 98.25% | 160.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 257.57% | 217.17% | 110.39% | 46.21% | -42.88% |